Keywords: Executive changes, Johnson & Johnson, AstraZeneca, Optimer Pharma

Senior exec changes actual or sought at Johnson & Johnson, AstraZeneca and Optimer

Article | 10 April 2012

Print This

US health care giant Johnson & Johnson (NYSE: JNJ) said on Monday that Sherilyn (Sheri) McCoy, vice chairman of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in